Goldshield Pharmaceuticals has submitted a POM to P switch application for cystitis treatment Cystobid.

The company argues that supply by trained pharmacists and pharmacy staff based on a protocol and a patient questionnaire would provide "an important new option" to women presenting with a new episode of symptoms typical with uncomplicated bacterial cystitis.The MHRA has launched a consultation on the application Submissions are to be made by April 14.